Gene Expression Assays

Advances in Clinical Chemistry

Volumn 44, Issue , 2007, Pages 247-292

  Kirby, Janine ^a   Heath, Paul R ^a   Shaw, Pamela J ^a   Hamdy, Freddie C ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA MICROARRAY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC PROCEDURES; HUMAN; MENTAL DISEASE; METHODOLOGY; NEOPLASM; NEUROLOGIC DISEASE; NUCLEIC ACID HYBRIDIZATION; REVIEW;

GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TECHNIQUES; HUMANS; MENTAL DISORDERS; NEOPLASMS; NERVOUS SYSTEM DISEASES; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 34347216651     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(07)44008-2     Document Type: Review

References (173)

1. Fodor S., Read J., Pirrung M., Stryer L., Lu A., and Solas D. Light-directed, spatially addressable parallel chemical synthesis. Science 251 4995 (1991) 767-773
2. Schena M., Shalon D., Davis R., and Brown P. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270 5235 (1995) 467-470
3. Schena M., Shalon D., Heller R., Chai A., Brown P., and Davis R. Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes. Proc Natl Acad Sci USA 93 20 (1996) 10614-10619
4. Shalon D., Smith S., and Brown P. A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization. Genome Res 6 7 (1996) 639-645
5. DeRisi J., Penland L., Brown P., Bittner M., Meltzer P., Ray M., et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 14 4 (1996) 457-460
6. Archacki S., and Wang Q. Expression profiling of cardiovascular disease. Hum Genomics 1 5 (2004) 355-370
7. Vigo T., Nobbio L., Hummelen P., Abbruzzese M., Mancardi G., Verpoorten N., et al. Experimental charcot-marie-tooth type 1A: A cDNA microarrays analysis. Mol Cell Neurosci 28 4 (2005) 703-714
8. Hedenfalk I., Duggan D., Chen Y., Radmacher M., Bittner M., Simon R., et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 344 8 (2001) 539-548
9. Valk P., Verhaak R., Beijen M., Erpelinck C., Barjesteh van Waalwijk van Doorn-Khosrovani S., et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350 16 (2004) 1617-1628
10. Ma X., Salunga R., Tuggle J., Gaudet J., Enright E., McQuary P., et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 100 10 (2003) 5974-5979
11. Glinsky G., Berezovska O., and Glinskii A. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115 6 (2005) 1503-1521
12. Modlich O., Prisack H., Munnes M., Audretsch W., and Bojar H. Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: Translation of microarray data into clinically useful predictive signatures. J Transl Med 3 (2005) 32
13. Gardian G., Browne S., Choi D., Klivenyi P., Gregorio J., Kubilus J., et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 280 1 (2005) 556-663
14. Murray J., Whitfield M., Trinklein N., Myers R., Brown P., and Botstein D. Diverse and specific gene expression responses to stresses in cultured human cells. Mol Biol Cell 15 5 (2004) 2361-2374
15. Thimmulappa R., Mai K., Srisuma S., Kensler T., Yamamoto M., and Biswal S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 62 18 (2002) 5196-5203
16. Matsuki T., Hori G., and Furuichi T. Gene expression profiling during the embryonic development of mouse brain using an oligonucleotide-based microarray system. Brain Res Mol Brain Res 136 1-2 (2005) 231-254
17. Lee C., Klopp R., Weindruch R., and Prolla T. Gene expression profile of aging and its retardation by caloric restriction. Science 285 5432 (1999) 1390-1393
18. Luo L., Salunga R., Guo H., Bittner A., Joy K., Galindo J., et al. Gene expression profiles of laser-captured adjacent neuronal subtypes. Nat Med 5 1 (1999) 117-122
19. Takamatsu K., Tachibana N., Matsumoto I., and Abe K. Soy protein functionality and nutrigenomic analysis. Biofactors 21 1-4 (2004) 49-53
20. Roy S., and Sen C. cDNA microarray screening in food safety. Toxicology 221 1 (2006) 128-133
21. Jansen A., and Yu J. Differential gene expression of pathogens inside infected hosts. Curr Opin Microbiol 9 2 (2006) 138-142
22. Brazas M., and Hancock R. Using microarray gene signatures to elucidate mechanisms of antibiotic action and resistance. Drug Discov Today 10 18 (2005) 1245-1252
23. Vert G., Nemhauser J., Geldner N., Hong F., and Chory J. Molecular mechanisms of steroid hormone signaling in plants. Annu Rev Cell Dev Biol 21 (2005) 177-201
24. Sharma P., Sharma N., and Deswal R. The molecular biology of the low-temperature response in plants. Bioessays 27 10 (2005) 1048-1059
25. Duggan D., Bittner M., Chen Y., Meltzer P., and Trent J. Expression profiling using cDNA microarrays. Nat Genet 21 1 Suppl (1999) 10-14
26. Stoughton R. Applications of DNA microarrays in biology. Annu Rev Biochem 74 (2005) 53-82
27. Fields RDO N. Gene chips: Applications to neuroscience. Neuroscientist 6 5 (2000) 310-314
28. Hacia J., Brody L., and Collins F. Applications of DNA chips for genomic analysis. Mol Psychiatry 3 6 (1998) 483-492
29. Southern E., Mir K., and Shchepinov M. Molecular interactions on microarrays. Nat Genet 21 1 Suppl (1999) 5-9
30. Schulze A., and Downward J. Navigating gene expression using microarrays-a technology review. Nat Cell Biol 3 8 (2001) E190-E195
31. Lipshutz R., Fodor S., Gingeras T., and Lockhart D. High density synthetic oligonucleotide arrays. Nat Genet 21 1 Suppl (1999) 20-24
32. Knudsen S. Guide to Microarray Analysis. 2nd ed. (2004), Wiley Press, Hoboken, New Jersey
33. Murray G., and Curran S. Laser Capture Microdissection (2005), Humana Press, Totowa, New Jersey
34. Feldman A., Costouros N., Wang E., Qian M., Marincola F., Alexander H., et al. Advantages of mRNA amplification for microarray analysis. Biotechniques 33 4 (2002) 906-912
35. Luzzi V., Mahadevappa M., Raja R., Warrington J., and Watson M. Accurate and reproducible gene expression profiles from laser capture microdissection, transcript amplification, and high density oligonucleotide microarray analysis. J Mol Diagn 5 1 (2003) 9-14
36. Alizadeh A., Eisen M., Davis R., Ma C., Lossos I., Rosenwald A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 6769 (2000) 503-511
37. Basil C., Zhao Y., Zavaglia K., Jin P., Panelli M., Voiculescu S., et al. Common cancer biomarkers. Cancer Res 66 6 (2006) 2953-2961
38. Quackenbush J. Microarray analysis and tumor classification. N Engl J Med 354 23 (2006) 2463-2472
39. Alon U., Barkai N., Notterman D., Gish K., Ybarra S., Mack D., et al. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci USA 96 12 (1999) 6745-6750
40. Golub T., Slonim D., Tamayo P., Huard C., Gaasenbeek M., Mesirov J., et al. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 286 5439 (1999) 531-537
41. Perou C., Jeffrey S., van de Rijn M., Rees C., Eisen M., Ross D., et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 96 16 (1999) 9212-9217
42. Brazma A., Hingamp P., Quackenbush J., Sherlock G., Spellman P., Stoeckert C., et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 29 4 (2001) 365-371
43. Galamb O., Sipos F., Fischer K., Tulassay Z., and Molnar B. The results of the expression array studies correlate and enhance the known genetic basis of gastric and colorectal cancer. Cytometry B Clin Cytom 68 1 (2005) 1-17
44. Tomioka H., Morita K., Hasegawa S., and Omura K. Gene expression analysis by cDNA microarray in oral squamous cell carcinoma. J Oral Pathol Med 35 4 (2006) 206-211
45. Calvo A., Gonzalez-Moreno O., Yoon C., Huh J., Desai K., Nguyen Q., et al. Prostate cancer and the genomic revolution: Advances using microarray analyses. Mutat Res 576 1-2 (2005) 66-79
46. Gordon G. Transcriptional profiling of mesothelioma using microarrays. Lung Cancer 49 Suppl 1 (2005) S99-S103
47. Almstrup K., Ottesen A., Sonne S., Hoei-Hansen C., Leffers H., Rajpert-De Meyts E., et al. Genomic and gene expression signature of the pre-invasive testicular carcinoma in situ. Cell Tissue Res 322 1 (2005) 159-165
48. Segal E., Friedman N., Kaminski N., Regev A., and Koller D. From signatures to models: Understanding cancer using microarrays. Nat Genet 37 Suppl. (2005) S38-S45
49. Bertucci F., Houlgatte R., Benziane A., Granjeaud S., Adelaide J., Tagett R., et al. Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum Mol Genet 9 20 (2000) 2981-2991
50. Easton D. Familial risks of breast cancer. Breast Cancer Res 4 5 (2002) 179-181
51. Malone K., Daling J., Doody D., Hsu L., Bernstein L., Coates R., et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black american women ages 35 to 64 years. Cancer Res 66 16 (2006) 8297-8308
52. Perou C., Sorlie T., Eisen M., van de Rijn M., Jeffrey S., Rees C., et al. Molecular portraits of human breast tumours. Nature 406 6797 (2000) 747-752
53. Sotiriou C., Neo S., McShane L., Korn E., Long P., Jazaeri A., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100 18 (2003) 10393-10398
54. van de Vijver M., He Y., van't Veer L., Dai H., Hart A., Voskuil D., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 25 (2002) 1999-2009
55. Sgroi D., Teng S., Robinson G., LeVangie R., Hudson Jr. J., and Elkahloun A. In vivo gene expression profile analysis of human breast cancer progression. Cancer Res 59 22 (1999) 5656-5661
56. Ma X., Salunga R., Tuggle J., Gaudet J., Enright E., McQuarry P., et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 100 (2003) 5974-5979
57. Wang Y., Klijn J., Zhang Y., Sieuwerts A., Look M., Yang F., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 9460 (2005) 671-679
58. Schuetz C., Bonin M., Clare S., Nieselt K., Sotlar K., Walter M., et al. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res 66 10 (2006) 5278-5286
59. Chang J., Wooten E., Tsimelzon A., Hilsenbeck S., Gutierrez M., Elledge R., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362 9381 (2003) 362-369
60. Ayers M., Symmans W., Stec J., Damokosh A., Clark E., Hess K., et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22 12 (2004) 2284-2293
61. Hayashi S., and Yamaguchi Y. Basic research for hormone-sensitivity of breast cancer. Breast Cancer 13 2 (2006) 123-128
62. Brenton J., Carey L., Ahmed A., and Caldas C. Molecular classification and molecular forecasting of breast cancer: Ready for clinical application?. J Clin Oncol 23 29 (2005) 7350-7360
63. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J., Nobel A., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100 14 (2003) 8418-8423
64. Dunphy C. Gene expression profiling data in lymphoma and leukemia: Review of the literature and extrapolation of pertinent clinical applications. Arch Pathol Lab Med 130 4 (2006) 483-520
65. Bullinger L., Dohner K., Bair E., Frohling S., Schlenk R., Tibshirani R., et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 350 16 (2004) 1605-1616
66. Wulfkuhle J., Espina V., Liotta L., and Petricoin E. Genomic and proteomic technologies for individualisation and improvement of cancer treatment. Eur J Cancer 40 17 (2004) 2623-2632
67. Liotta L., and Petricoin E. Molecular profiling of human cancer. Nat Rev Genet 1 1 (2000) 48-56
68. Vonsattel J., Myers R., Stevens T., Ferrante R., Bird E., and Richardson Jr. E. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44 6 (1985) 559-577
69. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72 6 (1993) 971-983
70. Luthi-Carter R., Strand A., Peters N., Solano S., Hollingsworth Z., Menon A., et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet 9 9 (2000) 1259-1271
71. Luthi-Carter R., Strand A., Hanson S., Kooperberg C., Schilling G., La Spada A., et al. Polyglutamine and transcription: Gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum Mol Genet 11 17 (2002) 1927-1937
72. Luthi-Carter R., Hanson S., Strand A., Bergstrom D., Chun W., Peters N., et al. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: Parallel changes in muscle and brain. Hum Mol Genet 11 17 (2002) 1911-1926
73. Chan E., Luthi-Carter R., Strand A., Solano S., Hanson S., DeJohn M., et al. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Hum Mol Genet 11 17 (2002) 1939-1951
74. Hodges A., Strand A., Aragaki A., Kuhn A., Sengstag T., Hughes G., et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 15 6 (2006) 965-977
75. Ferrante R., Kubilus J., Lee J., Ryu H., Beesen A., Zucker B., et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 23 28 (2003) 9418-9427
76. Morton A., Hunt M., Hodges A., Lewis P., Redfern A., Dunnett S., et al. A combination drug therapy improves cognition and reverses gene expression changes in a mouse model of Huntington's disease. Eur J Neurosci 21 4 (2005) 855-870
77. Borovecki F., Lovrecic L., Zhou J., Jeong H., Then F., Rosas H., et al. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc Natl Acad Sci USA 102 31 (2005) 11023-11028
78. Kim Y., Yi Y., Sapp E., Wang Y., Cuiffo B., Kegel K., et al. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc Natl Acad Sci USA 98 22 (2001) 12784-12789
79. Cha J. Transcriptional dysregulation in Huntington's disease. Trends Neurosci 23 9 (2000) 387-392
80. Van Lint C., Emiliani S., and Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 5 4-5 (1996) 245-253
81. Steffan J., Kazantsev A., Spasic-Boskovic O., Greenwald M., Zhu Y., Gohler H., et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci USA 97 12 (2000) 6763-6768
82. Alarcon J., Malleret G., Touzani K., Vronskaya S., Ishii S., Kandel E., et al. Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice: A model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron 42 6 (2004) 947-959
83. Tarnopolsky M., and Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 52 4 (1999) 854-857
84. Klivenyi P., Ferrante R., Matthews R., Bogdanov M., Klein A., Andreassen O., et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 5 3 (1999) 347-350
85. Ide K., Nukina N., Masuda N., Goto J., and Kanazawa I. Abnormal gene product identified in Huntington's disease lymphocytes and brain. Biochem Biophys Res Commun 209 2 (1995) 1119-1125
86. Lassmann H., Raine C., Antel J., and Prineas J. Immunopathology of multiple sclerosis: Report on an international meeting held at the Institute of Neurology of the University of Vienna. J Neuroimmunol 86 2 (1998) 213-217
87. Whitney L., Becker K., Tresser N., Caballero-Ramos C., Munson P., Prabhu V., et al. Analysis of gene expression in mutiple sclerosis lesions using cDNA microarrays. Ann Neurol 46 3 (1999) 425-428
88. Whitney L., Ludwin S., McFarland H., and Biddison W. Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions. J Neuroimmunol 121 1-2 (2001) 40-48
89. Uz T., Dimitrijevic N., Tueting P., and Manev H. 5-Lipoxygenase (5LOX)-deficient mice express reduced anxiety-like behavior. Restor Neurol Neurosci 20 1-2 (2002) 15-20
90. Emerson M., and LeVine S. Experimental allergic encephalomyelitis is exacerbated in mice deficient for 12/15-lipoxygenase or 5-lipoxygenase. Brain Res 1021 1 (2004) 140-145
91. Carmody R., Hilliard B., Maguschak K., Chodosh L., and Chen Y. Genomic scale profiling of autoimmune inflammation in the central nervous system: The nervous response to inflammation. J Neuroimmunol 133 1-2 (2002) 95-107
92. Chabas D., Baranzini S., Mitchell D., Bernard C., Rittling S., Denhardt D., et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294 5547 (2001) 1731-1735
93. Steinman L., and Zamvil S. Transcriptional analysis of targets in multiple sclerosis. Nat Rev Immunol 3 6 (2003) 483-492
94. Tajouri L., Mellick A., Tourtellotte A., Nagra R., and Griffiths L. An examination of MS candidate genes identified as differentially regulated in multiple sclerosis plaque tissue, using absolute and comparative real-time Q-PCR analysis. Brain Res Brain Res Protoc 15 2 (2005) 79-91
95. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 8 5 (2002) 500-508
96. Mycko M., Papoian R., Boschert U., Raine C., and Selmaj K. cDNA microarray analysis in multiple sclerosis lesions: Detection of genes associated with disease activity. Brain 126 Pt 5 (2003) 1048-1057
97. Mirnics K., Korade Z., Arion D., Lazarov O., Unger T., Macioce M., et al. Presenilin-1-dependent transcriptome changes. J Neurosci 25 6 (2005) 1571-1578
98. Cai D., Leem J., Greenfield J., Wang P., Kim B., Wang R., et al. Presenilin-1 regulates intracellular trafficking and cell surface delivery of beta-amyloid precursor protein. J Biol Chem 278 5 (2003) 3446-3454
99. Saura C., Choi S., Beglopoulos V., Malkani S., Zhang D., Shankaranarayana Rao B., et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 42 1 (2004) 23-36
100. Yoshikai S., Sasaki H., Doh-ura K., Furuya H., and Sakaki Y. Genomic organization of the human-amyloid beta-protein precursor gene. Gene 102 2 (1991) 291-292
101. Sandbrink R., Masters C., and Beyreuther K. Beta A4-amyloid protein precursor mRNA isoforms without exon 15 are ubiquitously expressed in rat tissues including brain, but not in neurons. J Biol Chem 269 2 (1994) 1510-1517
102. De Strooper B., Saftig P., Craessaerts K., Vanderstichele H., Guhde G., Annaert W., et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391 6665 (1998) 387-390
103. Reddy P., McWeeney S., Park B., Manczak M., Gutala R., Partovi D., et al. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: Up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Hum Mol Genet 13 12 (2004) 1225-1240
104. Hirai K., Aliev G., Nunomura A., Fujioka H., Russell R., Atwood C., et al. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21 9 (2001) 3017-3023
105. Arendash G., King D., Gordon M., Morgan D., Hatcher J., Hope C., et al. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res 891 1-2 (2001) 42-53
106. Dickey C., Loring J., Montgomery J., Gordon M., Eastman P., and Morgan D. Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein+ presenilin-1 transgenic mice. J Neurosci 23 12 (2003) 5219-5226
107. Ginsberg S., Hemby S., Lee V., Eberwine J., and Trojanowski J. Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. Ann Neurol 48 1 (2000) 77-87
108. Blalock E., Geddes J., Chen K., Porter N., Markesbery W., and Landfield P. Incipient Alzheimer's disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA 101 7 (2004) 2173-2178
109. Ginsberg S., Che S., Counts S., and Mufson E. Single cell gene expression profiling in Alzheimer's disease. NeuroRx 3 3 (2006) 302-318
110. Ginsberg S., Crino P., Hemby S., Weingarten J., Lee V., Eberwine J., et al. Predominance of neuronal mRNAs in individual Alzheimer's disease senile plaques. Ann Neurol 45 2 (1999) 174-181
111. Ginsberg S., Che S., Wuu J., Counts S., and Mufson E. Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. J Neurochem 97 2 (2006) 475-487
112. Stutzmann G. Calcium dysregulation, IP3 signaling, and Alzheimer's disease. Neuroscientist 11 2 (2005) 110-115
113. Blalock E., Chen K., Stromberg A., Norris C., Kadish I., Kraner S., et al. Harnessing the power of gene microarrays for the study of brain aging and Alzheimer's disease: Statistical reliability and functional correlation. Ageing Res Rev 4 4 (2005) 481-512
114. Barber S., Mead R., and Shaw P. Oxidative stress in ALS: A mechanism of neurodegeneration and a therapeutic target. Biochim Biophys Acta 1762 11-12 (2006) 1051-1067
115. Heath P., and Shaw P. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve 26 4 (2002) 438-458
116. Wood J., Beaujeux T., and Shaw P. Protein aggregation in motor neurone disorders. Neuropathol Appl Neurobiol 29 6 (2003) 529-545
117. Menzies F., Ince P., and Shaw P. Mitochondrial involvement in amyotrophic lateral sclerosis. Neurochem Int 40 6 (2002) 543-551
118. Kunst C. Complex genetics of amyotrophic lateral sclerosis. Am J Hum Genet 75 6 (2004) 933-947
119. Rosen D., Siddique T., Patterson D., Figlewicz D., Sapp P., Hentati A., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362 6415 (1993) 59-62
120. Gurney M., Pu H., Chiu A., Dal Canto M., Polchow C., Alexander D., et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264 5166 (1994) 1772-1775
121. Olsen M., Roberds S., Ellerbrock B., Fleck T., McKinley D., and Gurney M. Disease mechanisms revealed by transcription profiling in SOD1-G93A transgenic mouse spinal cord. Ann Neurol 50 6 (2001) 730-740
122. Yoshihara T., Ishigaki S., Yamamoto M., Liang Y., Niwa J., Takeuchi H., et al. Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 80 1 (2002) 158-167
123. Dangond F., Hwang D., Camelo S., Pasinelli P., Frosch M., Stephanopoulos G., et al. Molecular signature of late-stage human ALS revealed by expression profiling of postmortem spinal cord gray matter. Physiol Genomics 16 2 (2004) 229-239
124. Ishigaki S., Niwa J., Ando Y., Yoshihara T., Sawada K., Doyu M., et al. Differentially expressed genes in sporadic amyotrophic lateral sclerosis spinal cords-screening by molecular indexing and subsequent cDNA microarray analysis. FEBS Lett 531 2 (2002) 354-358
125. Malaspina A., Kaushik N., and de Belleroche J. Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays. J Neurochem 77 1 (2001) 132-145
126. Kirby J., Halligan E., Baptista M., Allen S., Heath P., Holden H., et al. Mutant SOD1 alters the motor neuronal transcriptome: Implications for familial ALS. Brain 128 Pt 7 (2005) 1686-1706
127. Jiang Y., Yamamoto M., Kobayashi Y., Yoshihara T., Liang Y., Terao S., et al. Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Ann Neurol 57 2 (2005) 236-251
128. Perrin F., Boisset G., Docquier M., Schaad O., Descombes P., and Kato A. No widespread induction of cell death genes occurs in pure motoneurons in an amyotrophic lateral sclerosis mouse model. Hum Mol Genet 14 21 (2005) 3309-3320
129. Perrin F., Boisset G., Lathuiliere A., and Kato A. Cell death pathways differ in several mouse models with motoneurone disease: Analysis of pure motoneurone populations at a presymptomatic age. J Neurochem 98 6 (2006) 1959-1972
130. Perrin F., Boisset G., Lathuiliere A., and Kato A. Cell death pathways differ in several mouse models with motoneurone disease: Analysis of pure motoneurone populations at a presymptomatic age. J Neurochem 98 6 (2006) 1959-1972
131. Bommel H., Xie G., Rossoll W., Wiese S., Jablonka S., Boehm T., et al. Missense mutation in the tubulin-specific chaperone E (Tbce) gene in the mouse mutant progressive motor neuronopathy, a model of human motoneuron disease. J Cell Biol 159 4 (2002) 563-569
132. Schmitt-John T., Drepper C., Mussmann A., Hahn P., Kuhlmann M., Thiel C., et al. Mutation of Vps54 causes motor neuron disease and defective spermiogenesis in the wobbler mouse. Nat Genet 37 11 (2005) 1213-1215
133. Youdim M. What have we learnt from CDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease?. J Neural Transm Suppl 65 (2003) 73-88
134. Grunblatt E., Mandel S., Jacob-Hirsch J., Zeligson S., Amariglo N., Rechavi G., et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 111 12 (2004) 1543-1573
135. Mandel S., Grunblatt E., Riederer P., Amariglio N., Jacob-Hirsch J., Rechavi G., et al. Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann NY Acad Sci 1053 (2005) 356-375
136. Nishinaga H., Takahashi-Niki K., Taira T., Andreadis A., Iguchi-Ariga S., and Ariga H. Expression profiles of genes in DJ-1-knockdown and L 166 P DJ-1 mutant cells. Neurosci Lett 390 1 (2005) 54-59
137. Xiang W., Windl O., Westner I., Neumann M., Zerr I., Lederer R., et al. Cerebral gene expression profiles in sporadic Creutzfeldt-Jakob disease. Ann Neurol 58 2 (2005) 242-257
138. Tsuang M., Nossova N., Yager T., Tsuang M., Guo S., Shyu K., et al. Assessing the validity of blood-based gene expression profiles for the classification of schizophrenia and bipolar disorder: A preliminary report. Am J Med Genet B Neuropsychiatr Genet 133 1 (2005) 1-5
139. Mirnics K., Middleton F., Stanwood G., Lewis D., and Levitt P. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry 6 3 (2001) 293-301
140. Tkachev D., Mimmack M., Ryan M., Wayland M., Freeman T., Jones P., et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 362 9386 (2003) 798-805
141. Iwamoto K., Bundo M., and Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet 14 2 (2005) 241-253
142. Mirnics K., Middleton F., Marquez A., Lewis D., and Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 28 1 (2000) 53-67
143. Vawter M., Crook J., Hyde T., Kleinman J., Weinberger D., Becker K., et al. Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: A preliminary study. Schizophr Res 58 1 (2002) 11-20
144. Hemby S., Ginsberg S., Brunk B., Arnold S., Trojanowski J., and Eberwine J. Gene expression profile for schizophrenia: Discrete neuron transcription patterns in the entorhinal cortex. Arch Gen Psychiatry 59 7 (2002) 631-640
145. Middleton F., Mirnics K., Pierri J., Lewis D., and Levitt P. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci 22 7 (2002) 2718-2729
146. Li J., Vawter M., Walsh D., Tomita H., Evans S., Choudary P., et al. Systematic changes in gene expression in postmortem human brains associated with tissue pH and terminal medical conditions. Hum Mol Genet 13 6 (2004) 609-616
147. Hakak Y., Walker J., Li C., Wong W., Davis K., Buxbaum J., et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 98 8 (2001) 4746-4751
148. Aston C., Jiang L., and Sokolov B. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J Neurosci Res 77 6 (2004) 858-866
149. Sugai T., Kawamura M., Iritani S., Araki K., Makifuchi T., Imai C., et al. Prefrontal abnormality of schizophrenia revealed by DNA microarray: Impact on glial and neurotrophic gene expression. Ann NY Acad Sci 1025 (2004) 84-91
150. Bezchlibnyk Y., Wang J., McQueen G., and Young L. Gene expression differences in bipolar disorder revealed by cDNA array analysis of post-mortem frontal cortex. J Neurochem 79 4 (2001) 826-834
151. Brzustowicz L., Hodgkinson K., Chow E., Honer W., and Bassett A. Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-q22. Science 288 5466 (2000) 678-682
152. Chowdari K., Mirnics K., Semwal P., Wood J., Lawrence E., Bhatia T., et al. Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum Mol Genet 11 12 (2002) 1373-1380
153. Morris D., Rodgers A., McGhee K., Schwaiger S., Scully P., Quinn J., et al. Confirming RGS4 as a susceptibility gene for schizophrenia. Am J Med Genet B Neuropsychiatr Genet 125 1 (2004) 50-53
154. Williams N., Preece A., Spurlock G., Norton N., Williams H., McCreadie R., et al. Support for RGS4 as a susceptibility gene for schizophrenia. Biol Psychiatry 55 2 (2004) 192-195
155. Chen X., Dunham C., Kendler S., Wang X., O'Neill F., Walsh D., et al. Regulator of G-protein signaling 4 (RGS4) gene is associated with schizophrenia in Irish high density families. Am J Med Genet B Neuropsychiatr Genet 129 1 (2004) 23-26
156. Sobell J., Richard C., Wirshing D., and Heston L. Failure to confirm association between RGS4 haplotypes and schizophrenia in Caucasians. Am J Med Genet B Neuropsychiatr Genet 139 1 (2005) 23-27
157. Brzustowicz L., Simone J., Mohseni P., Hayter J., Hodgkinson K., Chow E., et al. Linkage disequilibrium mapping of schizophrenia susceptibility to the CAPON region of chromosome 1q22. Am J Hum Genet 74 5 (2004) 1057-1063
158. Talkowski M., Seltman H., Bassett A., Brzustowicz L., Chen X., Chowdari K., et al. Evaluation of a susceptibility gene for schizophrenia: Genotype based meta-analysis of RGS4 polymorphisms from thirteen independent samples. Biol Psychiatry 60 2 (2006) 152-162
159. Aston C., Jiang L., and Sokolov B. Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Mol Psychiatry 10 3 (2005) 309-322
160. Uranova N., Vostrikov V., Orlovskaya D., and Rachmanova V. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: A study from the Stanley Neuropathology Consortium. Schizophr Res 67 2-3 (2004) 269-275
161. Hamidi M., Drevets W., and Price J. Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol Psychiatry 55 6 (2004) 563-569
162. Steingard R., Renshaw P., Hennen J., Lenox M., Cintron C., Young A., et al. Smaller frontal lobe white matter volumes in depressed adolescents. Biol Psychiatry 52 5 (2002) 413-417
163. Hoheisel J. Microarray technology: Beyond transcript profiling and genotype analysis. Nat Rev Genet 7 3 (2006) 200-210
164. ENCODE Project Consortium. The ENCODE(ENCyclopedia Of DNA Elements) Project. Science 306 5696 (2004) 636-640
165. Kampa D., Cheng J., Kapranov P., Yamanaka M., Brubaker S., Cawley S., et al. Novel RNAs identified from an in-depth analysis of the transcriptome of human chromosomes 21 and 22. Genome Res 14 3 (2004) 331-342
166. Cawley S., Bekiranov S., Ng H., Kapranov P., Sekinger E., Kampa D., et al. Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell 116 4 (2004) 499-509
167. Gingeras T. The multitasking genome. Nat Genet 38 6 (2006) 608-609
168. Ren B., Robert F., Wyrick J., Aparicio O., Jennings E., Simon I., et al. Genome-wide location and function of DNA binding proteins. Science 290 5500 (2000) 2306-2309
169. Buck M., and Lieb J. ChIP-chip: Considerations for the design, analysis, and application of genome-wide chromatin immunoprecipitation experiments. Genomics 83 3 (2004) 349-360
170. Weinmann A., Yan P., Oberley M., Huang T., and Farnham P. Isolating human transcription factor targets by coupling chromatin immunoprecipitation and CpG island microarray analysis. Genes Dev 16 2 (2002) 235-244
171. Weinmann A., and Farnham P. Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation. Methods 26 1 (2002) 37-47
172. Carroll J., Liu X., Brodsky A., Li W., Meyer C., Szary A., et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122 1 (2005) 33-43
173. Sebat J., Lakshmi B., Troge J., Alexander J., Young J., Lundin P., et al. Large-scale copy number polymorphism in the human genome. Science 305 5683 (2004) 525-528